VIDO funded $24M to help develop 'holy grail' coronavirus vaccine
Social Sharing
The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan has been awarded a $24 million grant to help develop a vaccine to protect against wide-ranging strains of coronaviruses.
VIDO's funding flows from Norwegian-based Coalition for Epidemic Preparedness Innovations (CEPI) into its ongoing development of its pan-sarbecovirus vaccine.
Dr. Nicole Lurie, Executive Director of Emergency Preparedness at CEPI, said the vaccine is designed by combining fragments of several different coronaviruses into a single vaccine.
VIDO's goal is to develop a vaccine that would improve a person's resistance to SARS-CoV-1 and SARS-CoV-2, the virus that led to the COVID-19 pandemic, as well as future coronaviruses, limiting how much resources are spent on new vaccines to match different strains of the virus.
Lurie referred to it as a sort of "holy grail."
"By acting now, we can try to get ahead of coronavirus and their variants before they evolve to get ahead of us. Our goal is to be sure that the world is never again hit by a coronavirus pandemic," said Lurie.
Dr. Volker Gerdts, the director and CEO of VIDO said it's possible to use different tools — artificial intelligence, bioinformatics — to predict what the next virus pathogen will look like and prepare vaccines to combat them.
"It's all about predicting what is coming in the future and being ready for it," said Gerdts.
"As we just learned during the pandemic, Canada was not quite ready for it this time. So let's make sure that next time we're better prepared."
VIDO's vaccine is also anticipated to be thermostable, meaning it won't need to be in a temperature-controlled environment when it's transported or stored.
That opens it up to use in low- and middle-income countries and in regions with less resources to allow for better access to vaccines.
"We saw what the COVID pandemic did to our economy, did to our families, did to our small businesses and you know, we want to be prepared," said Terry Duguid, the federal Minister Responsible for Prairies Economic Development Canada (PrairiesCan).
PrairiesCan also provided VIDO with $30 million to expand, including a new animal housing facility and the ability to upgrade to the highest level of containment to work with any form of human or animal pathogen.
VIDO also received funding from CEPI in 2021 for an earlier project on a variant-proof COVID-19 vaccine.
The Coalition for Epidemic Preparedness was founded by the Indian and Norwegian governments, Bill and Melinda Gates Foundation, Wellcome and the World Economic Forum. It's supported by several pharmaceutical companies including Johnson & Johnson and Pfizer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
2 hours ago
- Toronto Star
Hundreds of laid-off CDC employees are being reinstated
NEW YORK (AP) — More than 460 laid-off employees at the nation's top public health agency received notices Wednesday that they are being reinstated, according to a union representing the workers. The U.S. Department of Health and Human Services confirmed reinstatement notices went out to the former Centers for Disease Control and Prevention employees, but provided few details. About 2,400 CDC employees lost their jobs in a wave of cuts across federal health agencies in early April, according to a tally at the time. ARTICLE CONTINUES BELOW Whole CDC programs were essentially shut down, including some focused on smoking, lead poisoning, gun violence, asthma and air quality, and workplace safety and health. The entire office that handles Freedom of Information Act requests was shuttered. Infectious disease programs took a hit, too, including programs that fight outbreaks in other countries, labs focused on HIV and hepatitis in the U.S., and staff trying to eliminate tuberculosis. An estimated 200 of the reinstated workers are based in the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, HHS officials confirmed. Staffers at a CDC lab that does testing for sexually transmitted diseases are being brought back, said one CDC employee who wasn't authorized to discuss what happened and spoke to The Associated Press on condition of anonymity. Also reinstated are an estimated 150 employees at the CDC's National Center for Environmental Health, including people staffing a lab that works on lead poisoning, according to the union and employees. Layoffs at federal agencies were challenged in lawsuits, with judges in some cases ordering federal agencies to halt terminations of employees. Officials at HHS have never detailed how they made the layoff decisions in the first place. And they did not answer questions about why the notices went out, or how decisions were made about who to bring back. HHS spokesperson Andrew Nixon said the agency was streamlining operations and that 'the nation's critical public health functions remain intact and effective.' ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW 'The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through NIOSH, safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases,' he said. This is not the first time that employees at the Atlanta-based agency were told they were being terminated only to then be told to come back. After an earlier round of termination notices went out in February, about 180 CDC employees in March were told to come back. __ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Japan Forward
16 hours ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む
Toronto Star
a day ago
- Toronto Star
Would you ever just stop washing your face? Inside the viral ‘caveman beauty' trend
The Paleo trend has come for your face: ' Caveman skin' is the latest beauty routine taking over social media. After circulating on Reddit for a few years, it was popularized this spring by Montreal-based TikTokker Tia Zakher, who went viral on the app for going about three months without putting anything on her face — no water, no cleanser, no moisturizer, nothing. The idea is that it's an elimination diet for your skin; an epidermal reset, if you will. 'For years, I picked and over-exfoliated and damaged my skin really badly … My skin is basically shedding all the damage and attempting to reregulate itself,' Zakher says in a video about the trend. Over the course of her attempt, which she says she did with guidance from her dermatologist, her skin looks as if it's pilling and then peeling off.
